Genetically proxied SGLT2 inhibition lowered the risk of advanced (OR = 0.52, 95% CI = 0.27 to 0.99; p = 0.049) and early-onset (OR = 0.27, 95% CI = 0.11 to 0.71; p = 0.008) prostate cancer. Here, SLC5A2 is linked to prostate cancer.